Telaprevir Simmering, Flush Vertex Raises $320 Million More
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm moves away from “science-based” buyers and herds three institutional, longer-view backers into a single public offering.
You may also be interested in...
Vertex's Latest Finance Play: Selling Off EU Milestone Payments For Telaprevir
Curious announcement could presage a deal already in place or be an effort to draw competing bids.
Vertex's Latest Finance Play: Selling Off EU Milestone Payments For Telaprevir
Curious announcement could presage a deal already in place or be an effort to draw competing bids.
For U.S. Biotechs, Money Is Available Again But It Doesn’t Come Cheap
Oncothyreon is typical of many small publicly traded biotechs these days: the Seattle-based biotech finished the first quarter of 2009 with just $15.4 million in cash and equivalents, necessitating a careful husbanding of finances. But because it's been enjoying a recent uptick in market cap, the oncology-focused biotech raised $11.1 million via a registered direct offering